An international survey seeks to determine the most important outcomes to measure in Phase 3 trials of pulmonary TB treatment.
As part of UNITE4TB and the COMET initiative, an international survey, led by the University of Liverpool, seeks to determine the most important outcomes to measure in Phase 3 trials when researching new treatments for pulmonary TB to help identify what treatments suit patients best and to ensure trial results can be more easily compared. The survey aims to collect the perspectives of TB researchers, healthcare workers, survivors and carers from a range of countries.
Purpose: To identify core outcomes for measurement in Phase 3 trials of pulmonary TB.
Time commitment: The survey is designed to be concise, taking approximately 20 minutes to complete.
Confidentiality: All responses will be kept confidential, and aggregated findings will be shared with participants. Ethics approval has been granted from the University of Liverpool.